SG10201406651PA - A pharmaceutical composition for treating cancer comprising trypsinogen and/orchymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compoundand a cytoplasmic glycolysis reduction agent - Google Patents
A pharmaceutical composition for treating cancer comprising trypsinogen and/orchymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compoundand a cytoplasmic glycolysis reduction agentInfo
- Publication number
- SG10201406651PA SG10201406651PA SG10201406651PA SG10201406651PA SG10201406651PA SG 10201406651P A SG10201406651P A SG 10201406651PA SG 10201406651P A SG10201406651P A SG 10201406651PA SG 10201406651P A SG10201406651P A SG 10201406651PA SG 10201406651P A SG10201406651P A SG 10201406651PA
- Authority
- SG
- Singapore
- Prior art keywords
- orchymotrypsinogen
- compoundand
- trypsinogen
- vanilloid
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2009905147A AU2009905147A0 (en) | 2009-10-22 | Pharmaceutical Compositions | |
| AU2010902655A AU2010902655A0 (en) | 2010-06-17 | Cancer Cell Regulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201406651PA true SG10201406651PA (en) | 2014-11-27 |
Family
ID=43899732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201406651PA SG10201406651PA (en) | 2009-10-22 | 2010-10-22 | A pharmaceutical composition for treating cancer comprising trypsinogen and/orchymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compoundand a cytoplasmic glycolysis reduction agent |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9636359B2 (es) |
| EP (2) | EP2490711A4 (es) |
| JP (1) | JP5871805B2 (es) |
| KR (1) | KR101936439B1 (es) |
| CN (2) | CN107625957B (es) |
| AU (1) | AU2010310887B9 (es) |
| BR (1) | BR112012009521B1 (es) |
| CA (1) | CA2814958C (es) |
| CL (1) | CL2012001019A1 (es) |
| DK (1) | DK3095458T3 (es) |
| ES (1) | ES2692377T3 (es) |
| HK (1) | HK1249017A1 (es) |
| IL (1) | IL219216A (es) |
| MX (1) | MX355971B (es) |
| NZ (1) | NZ599996A (es) |
| PE (1) | PE20121709A1 (es) |
| PT (1) | PT3095458T (es) |
| RU (1) | RU2012120785A (es) |
| SG (1) | SG10201406651PA (es) |
| TR (1) | TR201815315T4 (es) |
| WO (1) | WO2011047434A1 (es) |
| ZA (1) | ZA201203689B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2692377T3 (es) | 2009-10-22 | 2018-12-03 | Propanc Pty Ltd | Composición farmacéutica para tratar el cáncer que comprende tripsinógeno y quimotripsinógeno |
| RU2663127C2 (ru) * | 2013-03-15 | 2018-08-01 | Олтек, Инк. | Селенсодержащие композиции и их применение для лечения и предотвращения заболеваний или состояний, связанных с митохондриальной дисфункцией |
| CZ307195B6 (cs) | 2013-11-18 | 2018-03-14 | František Trnka | Farmaceutická kompozice obsahující směs proenzymů a enzymů |
| KR102466389B1 (ko) * | 2014-03-14 | 2022-11-11 | 올텍 법인회사 | 셀레노유기 화합물의 조성물 및 이의 사용 방법 |
| US9907786B2 (en) | 2014-10-21 | 2018-03-06 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof |
| US10092550B2 (en) | 2014-10-21 | 2018-10-09 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof |
| US20160106687A1 (en) | 2014-10-21 | 2016-04-21 | Life Plus, LLC | Human therapeutic agents |
| ES2941348T3 (es) | 2015-11-12 | 2023-05-22 | Propanc Pty Ltd | Composición de proenzima |
| CA3012398A1 (en) * | 2016-01-29 | 2017-08-03 | Propanc Pty Ltd | Cancer treatment based on chymotrypsinogen and trypsinogen |
| JP7004665B2 (ja) * | 2016-04-12 | 2022-02-04 | プロパンク・ピーティーワイ・リミテッド | 癌治療用の前酵素の組成物 |
| EP3517117A1 (en) * | 2018-01-30 | 2019-07-31 | Medizinische Universität Wien | Medicament for prevention or treatment of rhinovirus infection |
| WO2022261440A1 (en) * | 2021-06-11 | 2022-12-15 | Sorrento Therapeutics, Inc. | Administration of resiniferatoxin for treatment of pancreatic cancer |
| EP4389913A1 (en) * | 2022-12-23 | 2024-06-26 | Universität Heidelberg | A pcr-elisa analogous antibody-free method for detecting a target nucleic acid in a sample |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4514388A (en) * | 1983-03-22 | 1985-04-30 | Psaledakis Nicholas G | Proteolytic enzymes in the zymogen form to treat sarcoma cells |
| US4978332A (en) * | 1987-09-28 | 1990-12-18 | Matrix Pharmaceutical, Inc. | Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| FR2727107B1 (fr) * | 1994-11-21 | 1996-12-27 | Saint Gobain Vitrage | Vitrage muni d'au moins une couche mince et son procede d'obtention |
| CZ283972B6 (cs) | 1995-05-17 | 1998-07-15 | František Mudr. Trnka | Farmaceutický prostředek s modulačním účinkem na zhoubné nádory a jeho použití |
| CN1121218C (zh) * | 2000-03-08 | 2003-09-17 | 台湾东洋药品工业股份有限公司 | 酞胺哌啶酮在治疗肝细胞癌的药物组合物中的应用 |
| US6670330B1 (en) * | 2000-05-01 | 2003-12-30 | Theodore J. Lampidis | Cancer chemotherapy with 2-deoxy-D-glucose |
| AU2002226650A1 (en) * | 2001-01-18 | 2002-07-30 | Arnold Hoffman | Redox therapy for tumors |
| CN1471925A (zh) * | 2002-08-02 | 2004-02-04 | 丛繁滋 | 更适于硬质肿瘤直接给药的含砷组合物、制剂及制备方法 |
| JP2004182674A (ja) * | 2002-12-05 | 2004-07-02 | Kureha Chem Ind Co Ltd | バニリル脂肪酸アミドを含む抗腫瘍医薬組成物 |
| CA2513399A1 (en) * | 2003-01-10 | 2004-07-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with 2-deoxyglucose |
| CN1787814A (zh) * | 2003-05-13 | 2006-06-14 | 健康研究股份有限公司 | 增加抗癌药剂抗肿瘤活性的方法 |
| DE10321725A1 (de) | 2003-05-14 | 2004-12-02 | Mucos Pharma Gmbh & Co | Enzymhaltige Zusammensetzungen, daraus hergestellte diätetische Lebensmittel und Arzneimittel und ihre Verwendung für medizinische Zwecke |
| CN1557482A (zh) * | 2004-02-04 | 2004-12-29 | 高春平 | 调节免疫功能、抗肿瘤的天然营养剂 |
| JP2006151965A (ja) * | 2004-10-28 | 2006-06-15 | Mi Tec:Kk | セレン含有組成物及びその製法 |
| CN101287481A (zh) * | 2005-05-26 | 2008-10-15 | 科学工业研究委员会 | 用于治疗肝细胞癌的药物组合物 |
| KR100740989B1 (ko) * | 2005-07-22 | 2007-07-19 | 넨시스(주) | 구형 항염·항암효소 과립제 및 이의 제조방법 |
| CN1944641B (zh) * | 2006-10-26 | 2010-11-03 | 上海林叶生物科技有限公司 | 高纯度糜蛋白酶的制备方法 |
| KR101058136B1 (ko) * | 2007-11-09 | 2011-08-24 | 신동헌 | 캡시에이트 또는 디하이드로캡시에이트의 신규한 용도 |
| ES2692377T3 (es) | 2009-10-22 | 2018-12-03 | Propanc Pty Ltd | Composición farmacéutica para tratar el cáncer que comprende tripsinógeno y quimotripsinógeno |
| CZ307195B6 (cs) * | 2013-11-18 | 2018-03-14 | František Trnka | Farmaceutická kompozice obsahující směs proenzymů a enzymů |
-
2010
- 2010-10-22 ES ES16174383.6T patent/ES2692377T3/es active Active
- 2010-10-22 KR KR1020127012943A patent/KR101936439B1/ko active IP Right Grant
- 2010-10-22 BR BR112012009521-8A patent/BR112012009521B1/pt not_active IP Right Cessation
- 2010-10-22 JP JP2012534496A patent/JP5871805B2/ja active Active
- 2010-10-22 MX MX2012004610A patent/MX355971B/es active IP Right Grant
- 2010-10-22 EP EP10824316A patent/EP2490711A4/en not_active Withdrawn
- 2010-10-22 PT PT16174383T patent/PT3095458T/pt unknown
- 2010-10-22 TR TR2018/15315T patent/TR201815315T4/tr unknown
- 2010-10-22 EP EP16174383.6A patent/EP3095458B1/en active Active
- 2010-10-22 RU RU2012120785/15A patent/RU2012120785A/ru not_active Application Discontinuation
- 2010-10-22 CN CN201710885368.4A patent/CN107625957B/zh active Active
- 2010-10-22 CN CN201080054056.5A patent/CN102639145B/zh active Active
- 2010-10-22 CA CA2814958A patent/CA2814958C/en active Active
- 2010-10-22 NZ NZ599996A patent/NZ599996A/en unknown
- 2010-10-22 AU AU2010310887A patent/AU2010310887B9/en active Active
- 2010-10-22 DK DK16174383.6T patent/DK3095458T3/en active
- 2010-10-22 PE PE2012000530A patent/PE20121709A1/es not_active Application Discontinuation
- 2010-10-22 WO PCT/AU2010/001403 patent/WO2011047434A1/en active Application Filing
- 2010-10-22 SG SG10201406651PA patent/SG10201406651PA/en unknown
- 2010-10-22 US US13/502,917 patent/US9636359B2/en active Active
-
2012
- 2012-04-16 IL IL219216A patent/IL219216A/en active IP Right Grant
- 2012-04-20 CL CL2012001019A patent/CL2012001019A1/es unknown
- 2012-05-21 ZA ZA2012/03689A patent/ZA201203689B/en unknown
-
2017
- 2017-03-17 US US15/462,655 patent/US10350239B2/en active Active
-
2018
- 2018-07-04 HK HK18108670.0A patent/HK1249017A1/zh unknown
-
2019
- 2019-05-31 US US16/428,581 patent/US20190388463A1/en not_active Abandoned
-
2022
- 2022-07-11 US US17/862,120 patent/US20230137573A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201406651PA (en) | A pharmaceutical composition for treating cancer comprising trypsinogen and/orchymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compoundand a cytoplasmic glycolysis reduction agent | |
| LTPA2020520I1 (lt) | Anti-CD38 plius kortikosteroidai, plius nekortikosteroidinis chemoterapinis agentas, skirti vėžio gydymui | |
| IL255752B (en) | Compounds, pharmaceutical preparations containing the same uses for the treatment of cardiovascular disease, inflammatory diseases and cancer | |
| IL251637A0 (en) | Pd-1 pharmaceutical preparations containing an antagonist for the treatment of inflammations and tumors | |
| HK1204277A1 (en) | Compositions and methods for treating demodex infestations | |
| IL226327A (en) | Nephrilicin inhibitors, pharmaceuticals containing them, and their use in the preparation of such preparations | |
| PL2532366T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| IL197121A0 (en) | Systems for programmable delivery of an active agent | |
| EP2532364A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER | |
| BRPI0720546A2 (pt) | Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto | |
| EP2093237A4 (en) | ANTICANCER AGENT COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT | |
| IL210185A0 (en) | Methods, compositions and systems for local delivery of drugs | |
| ZA201405405B (en) | Humanized anti-epiregulin antibody,and cancer therapeutic agent comprising said antibody as active ingredient | |
| IL205401A0 (en) | An orally - absorbed solid dose formulation for vancomycin | |
| EP2531025A4 (en) | METHOD FOR TREATING FUNGI FERTIONS, FUNGICIDAL COMPOSITIONS AND THEIR USE | |
| IL197212A0 (en) | Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same | |
| PL2327672T3 (pl) | Materiał na bazie zaprawy gipsowej zawierający środek zdolny do zatrzymywania formaldehydu | |
| BRPI0908635A2 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
| EP2512458A4 (en) | SYSTEM FOR DELIVERING A TOPIC ACTIVE MEDICINE OF LOW TOXICITY | |
| HK1162138A1 (en) | Skin-whitening agent, anti-aging agent, and anti-oxidant agent | |
| BRPI1007334A2 (pt) | composto, inibidor, medicamento, composição farmacêutica, uso de um composto, agente anticâncer,e , método para tratar câncer. | |
| IL222707B (en) | Steroid compounds of 16-chloro- and 16, 16-dichloro-(4-alpha, 4-beta)-17-beta-(2-oxo-2h-pyran-5-yl) and pharmaceutical preparations containing them | |
| EP2473506A4 (en) | COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER | |
| EP2910246A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER WITH ENOBLOCK AS AN ACTIVE SUBSTANCE | |
| PL2379056T3 (pl) | Stała kompozycja farmaceutyczna zawierająca co najmniej jeden środek stabilizujący |